Celeste Thomas, MD
Rheumatology · Summerville, SCNPI 1073690731
Payments from drug & device makers
Across 211 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Pfizer$518
- AstraZeneca$418
- UCB, Inc.$399
- GSK$307
- Novartis$279
- plus $1K from 15 others
What the payments were for
- Food & beverage$4,208100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 74 | $1,209 |
| Pfizer | 45 | $518 |
| AstraZeneca | 12 | $418 |
| UCB, Inc. | 17 | $399 |
| GSK | 10 | $307 |
| Novartis | 11 | $279 |
| Mallinckrodt Hospital Products Inc. | 7 | $200 |
| Boehringer Ingelheim | 6 | $128 |
| Lilly USA, LLC | 5 | $127 |
| Johnson & Johnson | 4 | $104 |
| AbbVie | 3 | $90 |
| Octapharma USA, Inc. | 1 | $87 |
| Fresenius Kabi USA, LLC | 4 | $81 |
| Sandoz | 3 | $57 |
| Radius Health, Inc. | 2 | $50 |
| Genentech USA, Inc. | 2 | $42 |
| Organon | 1 | $33 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Aurinia Pharma U.S., Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAPHNELO$125
How this compares
$4,208 in reported general payments places this provider in the 40th percentile of 123 rheumatology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 11 | $99,857 |
| Hydroxychloroquine Sulfate | 48 | $1,685 |
| MethotrexateMethotrexate Sodium | 50 | $1,288 |
| Prednisone | 73 | $605 |
| Duloxetine Hcl | 15 | $178 |
| Tramadol Hcl | 19 | $58 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Summerville
- Clarence LegertonSummerville$7.7M
- Gary FinkSummerville$6.9M
- William EdwardsSummerville$5.9M
- Colin EdgertonSummerville$4.6M
- Gregory NiemerSummerville$4.4M
- Jennifer MurphySummerville$4.4M
- Nicholas HoldgateSummerville$533K
- Richard SilverCharleston$1.6M
- Alan BrownGreenville$947K
- Mitchell FeinmanOrangeburg$824K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.